Management of cholestatic disease in 2017


Primary biliary cholangitis ( PBC ) and primary sclerosing cholangitis ( PSC ) are the most frequent chronic cholestatic liver diseases and serve as model diseases to discuss the management of cholestasis in 2017 in the lecture that is summarized in this report. PBC and PSC are characterized by inflammation and fibrosis of small intrahepatic ( PBC ) or larger intra- and/or extrahepatic ( PSC ) bile ducts. Bile duct damage leads to cholestasis and can progress to liver fibrosis and even cirrhosis. Various genetic, environmental and endogenous factors may contribute to the development of chronic cholestatic liver diseases, but the exact pathogenesis of PBC and PSC has not been clarified. Ursodeoxycholic acid ( UDCA ) is the standard treatment of PBC and is used also for other cholestatic conditions including PSC , and it exerts anticholestatic effects at adequate doses. Novel anticholestatic therapeutic options for patients not adequately responding to UDCA are under development or have, like obeticholic acid, already been proven to have efficacy when combined with UDCA in the treatment of PBC . The future role of immunomodulating/immunosuppressive drug regimens must be critically reviewed.

cholestasis , farnesoid X receptor , nuclear receptor agonists , peroxisome proliferator-activated
receptor α , ursodeoxycholic acid

About Speaker


Prof. Dr.


City: Amsterdam

Institution: Academic Medical Center, University of Amsterdam


Biography of Ulrich BEUERS

Ulrich Beuers is currently Professor of Gastroenterology and Hepatology and Head of Hepatology at the Amsterdam University Medical Centres, location AMC. After his medical studies in Ghent, Berlin and Freiburg and his dissertation he underwent postdoctoral training in Biochemistry at the University of Göttingen and clinical training as Internist and Gastroenterologist & Hepatologist at the University of Munich including a research period (and later a sabbatical) at the Yale University in New Haven. He became in 2001 a Professor of Internal Medicine in Munich and is since 2007 appointed in Amsterdam.
Professor Beuers serves as Associate Editor for the Journal of Hepatology (3rd term) and is/was Editorial Board Member of various other journals including Gut and Hepatology. He was Chairman of the Netherlands Association for the Study of the Liver (2012-2018), the Netherlands Education Board of Gastroenterology & Hepatology (2013-2017) and the EASL Clinical Practice Guideline Committee for cholestatic liver diseases (2008-2009). His research is focussed on mechanisms of action of UDCA in cholestasis, the ‘biliary bicarbonate umbrella’ in fibrosing cholangiopathies, pathogenesis of pruritus in cholestasis and the pathogenesis of IgG4-associated cholangitis.

View more